The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
54 / 208
Overall Ranking
170 / 4730
Industry
Healthcare Equipment & Supplies
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
54.333
Target Price
+78.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.84% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6110.46.
Overvalued
The company’s latest PE is -2.04, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 62.33M shares, decreasing 12.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 6.37M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.36.
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.